JP2019501867A5 - - Google Patents

Info

Publication number

JP2019501867A5

JP2019501867A5 JP2018517741A JP2018517741A JP2019501867A5 JP 2019501867 A5 JP2019501867 A5 JP 2019501867A5 JP 2018517741 A JP2018517741 A JP 2018517741A JP 2018517741 A JP2018517741 A JP 2018517741A JP 2019501867 A5 JP2019501867 A5 JP 2019501867A5

Authority

JP

Japan

Prior art keywords

optionally

pharmaceutical composition

compstatin analog

unit dose

laca

Prior art date

2016-10-07

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 12
• RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical group C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 claims 10
• 229920000642 polymer Polymers 0.000 claims 7
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 6
• 108010069514 Cyclic Peptides Proteins 0.000 claims 4
• 102000001189 Cyclic Peptides Human genes 0.000 claims 4
• 206010064930 age-related macular degeneration Diseases 0.000 claims 4
• 230000000295 complement effect Effects 0.000 claims 4
• 230000001404 mediated effect Effects 0.000 claims 4
• 125000006850 spacer group Chemical group 0.000 claims 4
• 239000002202 Polyethylene glycol Substances 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 208000035475 disorder Diseases 0.000 claims 3
• 208000002780 macular degeneration Diseases 0.000 claims 3
• 229920001223 polyethylene glycol Polymers 0.000 claims 3
• RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 claims 2
• DGRJZSGHEKZYHP-UHFFFAOYSA-N 2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]acetic acid Chemical compound NCCOCCOCCOCC(O)=O DGRJZSGHEKZYHP-UHFFFAOYSA-N 0.000 claims 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
• 150000001408 amides Chemical class 0.000 claims 2
• 150000001413 amino acids Chemical group 0.000 claims 2
• 125000004122 cyclic group Chemical group 0.000 claims 2
• 229920000765 poly(2-oxazolines) Polymers 0.000 claims 2
• 108090000765 processed proteins & peptides Proteins 0.000 claims 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
• 208000008069 Geographic Atrophy Diseases 0.000 claims 1
• 208000022873 Ocular disease Diseases 0.000 claims 1
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 claims 1
• 150000001875 compounds Chemical class 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 210000003743 erythrocyte Anatomy 0.000 claims 1
• 208000030533 eye disease Diseases 0.000 claims 1
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1